About
Sarah Howell has been Chief Executive Officer of Arecor since 2015. Through her leadership, Arecor has grown significantly into a publicly listed clinical stage biopharmaceutical company. Since her appointment, Sarah has led Arecor through a period of continued growth and transformation, playing an instrumental role in progressing its proprietary pipeline and strengthening important collaborations with global partners. Sarah has a background in clinical and commercial pharmaceutical product development, manufacturing, supply and licensing across a range of product types and therapeutic areas, with previous senior roles in the pharmaceutical industry including Vice President CMC & Technical Development at BTG Plc., and Director of Outsourced Manufacturing at UCB-Celltech. Sarah holds a BSc in Chemistry from the University of Birmingham and a Ph.D. in Physical Organic Chemistry from the University of St Andrews.
Position in the VCSift Database
- • 1,305 investors hold the Chief Executive Officer role in VCSift. Sarah Howell is one of them.
- • 8,972 investors are based in London, England, United Kingdom.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- London, UK
Contact Information
Find more investors like Sarah
Search Investors